The development, first reported by The New York Times, could be a setback for AstraZeneca which is yet to receive approval for its Covid-19 vaccines in the US.
According to a report in The New York Times last week, a mix-up at the Baltimore manufacturing plant ruined 15 million potential doses of the Johnson and Johnson Covid-19 vaccine.
Johnson and Johnson then said that the "quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorised to manufacture drug substance for our Covid-19 vaccine".
After taking charge of manufacturing its drug substance at the facility, the company said it was adding dedicated leaders for operations and quality, and significantly increasing the number of manufacturing, quality and technical operations personnel to work with the specialists already at Emergent.
Johnson and Johnson said that all of its Covid-19 vaccine doses distributed to date have met rigorous regulatory quality standards.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.